TVGN (Tevogen Bio Holdings) ROCE %: 0.00% (As of Mar. 2026)


TVGN Tevogen Bio Holdings Inc TVGN
10 GF Score
Price $7.00
! 4 Warning Signs
View Full Analysis

What is Tevogen Bio Holdings ROCE %?

Tevogen Bio Holdings TVGN -27.98% 10 ROCE % is 0.00% as of Mar. 2026. GuruFocus rates TVGN with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tevogen Bio Holdings's annualized ROCE % for the quarter that ended in Mar. 2026 was 0.00%.

Tevogen Bio Holdings  (NAS:TVGN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tevogen Bio Holdings ROCE % Related Terms

Tevogen Bio Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Tevogen Bio Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tevogen Bio Holdings ROCE % Chart

Tevogen Bio Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-214.56 2.42 -42.82 0.00 0.00

Tevogen Bio Holdings Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TVGN
10GF Score
Tevogen Bio Holdings Inc TVGN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tevogen Bio Holdings ROCE % Calculation

Tevogen Bio Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-26.08/( ( (3.462 - 9.043) + (4.383 - 7.068) )/ 2 )
=-26.08/( (-5.581+-2.685)/ 2 )
=-26.08/-4.133
=631.02 %

Tevogen Bio Holdings's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-21.5/( ( (4.383 - 7.068) + (4.921 - 7.269) )/ 2 )
=-21.5/( ( -2.685 + -2.348 )/ 2 )
=-21.5/-2.5165
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Tevogen Bio Holdings (TVGN) has a ROCE % of 0.00% as of Mar. 2026.
Is Tevogen Bio Holdings' ROCE % too high?
Tevogen Bio Holdings' current ROCE % is 0.00%. Overall, Tevogen Bio Holdings has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tevogen Bio Holdings' ROCE % compare to DARE and BOLD?
Tevogen Bio Holdings' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Tevogen Bio Holdings's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tevogen Bio Holdings stock overvalued right now?
Tevogen Bio Holdings (TVGN) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Tevogen Bio Holdings' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Tevogen Bio Holdings (TVGN), the current ROCE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tevogen Bio Holdings Business Description

Address 15 Independence Boulevard, Suite 210, Warren, NJ, USA, 07059
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
10GF Score

Get the complete analysis for TVGN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00
Price